$CARM
Carisma Therapeutics Inc

2024 Q3 Form 10-Q Financial Statement

#000148500324000015 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $9.200M
YoY Change 155.56%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.560M
YoY Change -7.49%
% of Gross Profit
Research & Development $15.31M
YoY Change -17.34%
% of Gross Profit
Depreciation & Amortization $255.0K
YoY Change -64.08%
% of Gross Profit
Operating Expenses $20.87M
YoY Change -14.92%
Operating Profit -$11.67M
YoY Change -44.34%
Interest Expense $508.0K
YoY Change -56.84%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$11.16M
YoY Change -43.6%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$11.16M
YoY Change -43.84%
Net Earnings / Revenue -121.33%
Basic Earnings Per Share -$0.27
Diluted Earnings Per Share -$0.27
COMMON SHARES
Basic Shares Outstanding 41.54M shares 41.54M shares
Diluted Shares Outstanding 41.54M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.36M
YoY Change -65.53%
Cash & Equivalents $40.36M
Short-Term Investments
Other Short-Term Assets $8.359M
YoY Change 63.9%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $50.72M
YoY Change -58.49%
LONG-TERM ASSETS
Property, Plant & Equipment $8.476M
YoY Change 11.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $142.0K
YoY Change -29.0%
Total Long-Term Assets $8.618M
YoY Change -20.3%
TOTAL ASSETS
Total Short-Term Assets $50.72M
Total Long-Term Assets $8.618M
Total Assets $59.34M
YoY Change -55.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.033M
YoY Change -18.25%
Accrued Expenses $9.241M
YoY Change -3.88%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $1.283M
YoY Change 6.92%
Total Short-Term Liabilities $15.62M
YoY Change -13.11%
LONG-TERM LIABILITIES
Long-Term Debt $502.0K
YoY Change -16.33%
Other Long-Term Liabilities $815.0K
YoY Change -54.95%
Total Long-Term Liabilities $815.0K
YoY Change -54.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.62M
Total Long-Term Liabilities $815.0K
Total Liabilities $58.98M
YoY Change -11.05%
SHAREHOLDERS EQUITY
Retained Earnings -$275.2M
YoY Change 35.77%
Common Stock $41.00K
YoY Change 2.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $360.0K
YoY Change
Total Liabilities & Shareholders Equity $59.34M
YoY Change -55.39%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$11.16M
YoY Change -43.84%
Depreciation, Depletion And Amortization $255.0K
YoY Change -64.08%
Cash From Operating Activities -$16.12M
YoY Change -13.1%
INVESTING ACTIVITIES
Capital Expenditures $106.0K
YoY Change -55.83%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$106.0K
YoY Change -100.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 73.00K
YoY Change -102.01%
NET CHANGE
Cash From Operating Activities -16.12M
Cash From Investing Activities -106.0K
Cash From Financing Activities 73.00K
Net Change In Cash -16.15M
YoY Change -218.95%
FREE CASH FLOW
Cash From Operating Activities -$16.12M
Capital Expenditures $106.0K
Free Cash Flow -$16.23M
YoY Change -13.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Entity Registrant Name
EntityRegistrantName
Carisma Therapeutics Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2025616
dei Entity Address Address Line1
EntityAddressAddressLine1
3675 Market Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 401
dei Entity Address City Or Town
EntityAddressCityOrTown
Philadelphia
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19104
dei City Area Code
CityAreaCode
267
dei Local Phone Number
LocalPhoneNumber
491-6422
dei Trading Symbol
TradingSymbol
CARM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41544975 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40362000 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26596712 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26596712 shares
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.67
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
330000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-19876000 usd
CY2023Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2023Q2 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
0 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
66705000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
dei Entity Central Index Key
EntityCentralIndexKey
0001485003
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36296
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77605000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10359000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2866000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
50721000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
80471000 usd
CY2024Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
6531000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
6764000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1945000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2173000 usd
CY2024Q2 us-gaap Assets
Assets
59339000 usd
CY2023Q4 us-gaap Assets
Assets
89554000 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2033000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3933000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9241000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7662000 usd
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
659000 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1413000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1179000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1391000 usd
CY2024Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1283000 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
544000 usd
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1222000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
965000 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41544975 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41544975 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40609915 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40609915 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
41000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
40000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
275561000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
271594000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-275242000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-245102000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
360000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
26532000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
59339000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89554000 usd
CY2024Q2 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
9197000 usd
CY2023Q2 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
3560000 usd
CY2024Q2 carm Deferred Financing Costs Noncurrent
DeferredFinancingCostsNoncurrent
142000 usd
CY2023Q4 carm Deferred Financing Costs Noncurrent
DeferredFinancingCostsNoncurrent
146000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
15617000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15908000 usd
CY2024Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
41250000 usd
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
45000000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
795000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
860000 usd
CY2024Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
502000 usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
328000 usd
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
815000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
926000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
58979000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
63022000 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
12594000 usd
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
6803000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15307000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18518000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32769000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35159000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5560000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6007000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11005000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15581000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
20867000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
24525000 usd
us-gaap Operating Expenses
OperatingExpenses
43774000 usd
us-gaap Operating Expenses
OperatingExpenses
50740000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11670000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20965000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-31180000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-43937000 usd
CY2024Q2 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
0 usd
CY2023Q2 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
0 usd
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
0 usd
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
-84000 usd
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
508000 usd
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1177000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1040000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-300000 usd
CY2024Q2 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-11162000 usd
CY2023Q2 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-19788000 usd
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-30140000 usd
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-44321000 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
88000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
197000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11162000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-19876000 usd
us-gaap Net Income Loss
NetIncomeLoss
-30140000 usd
us-gaap Net Income Loss
NetIncomeLoss
-44518000 usd
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.67
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41543553 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41543553 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40258107 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40258107 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41241009 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41241009 shares
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11162000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-19876000 usd
us-gaap Net Income Loss
NetIncomeLoss
-30140000 usd
us-gaap Net Income Loss
NetIncomeLoss
-44518000 usd
CY2024Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 usd
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
129000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
306000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11162000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19747000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30140000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44212000 usd
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2023Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
0 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
26532000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1057000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2282000 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-18978000 usd
CY2024Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2024Q1 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
0 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10895000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
625000 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-11162000 usd
CY2024Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2024Q2 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
0 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
360000 usd
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
8700885 shares
CY2022Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
107808000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-142670000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
265000 usd
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
177000 usd
CY2023Q1 carm Stock Issued During Period Values Preclosure Financing Transaction
StockIssuedDuringPeriodValuesPreclosureFinancingTransaction
30640000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
42447000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
72044000 usd
CY2023Q1 carm Reclassifications Of Temporary To Permanent Equity Shares
ReclassificationsOfTemporaryToPermanentEquityShares
-8700885 shares
CY2023Q1 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
-107808000 usd
CY2023Q1 carm Stock Issued During Period Shares Conversion Of Convertible Preferred Stock And Non Controlling Interests Upon Merger
StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger
107809000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-24642000 usd
CY2023Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2023Q1 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
0 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
86070000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
52000 usd
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
129000 usd
us-gaap Profit Loss
ProfitLoss
-30140000 usd
us-gaap Profit Loss
ProfitLoss
-44518000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1948000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1420000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1682000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
595000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4565000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2683000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1283000 usd
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
0 usd
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
-84000 usd
carm Accretion On Marketable Securities
AccretionOnMarketableSecurities
0 usd
carm Accretion On Marketable Securities
AccretionOnMarketableSecurities
569000 usd
carm Write Off Of Property And Equipment
WriteOffOfPropertyAndEquipment
67000 usd
carm Write Off Of Property And Equipment
WriteOffOfPropertyAndEquipment
0 usd
carm Noncash Interest Expense
NoncashInterestExpense
159000 usd
carm Noncash Interest Expense
NoncashInterestExpense
68000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7493000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1210000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1900000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
659000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1580000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1618000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4504000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1043000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4614000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1915000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
105000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38545000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44081000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
34460000 usd
carm Payments For Proceeds From Marketable Securities
PaymentsForProceedsFromMarketableSecurities
0 usd
carm Payments For Proceeds From Marketable Securities
PaymentsForProceedsFromMarketableSecurities
-67000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
123000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
382000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-123000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
32158000 usd
carm Cash Cash Equivalents And Restricted Cash Acquired In Reverse Recapitalization Financing Activities
CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities
0 usd
carm Cash Cash Equivalents And Restricted Cash Acquired In Reverse Recapitalization Financing Activities
CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities
37903000 usd
carm Payment Of Finance Costs Reverse Recapitalization Financing Activities
PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities
0 usd
carm Payment Of Finance Costs Reverse Recapitalization Financing Activities
PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities
5202000 usd
carm Proceeds From Issuance Of Common Stock Pre Closing Financing
ProceedsFromIssuanceOfCommonStockPreClosingFinancing
0 usd
carm Proceeds From Issuance Of Common Stock Pre Closing Financing
ProceedsFromIssuanceOfCommonStockPreClosingFinancing
30640000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
906000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
213000 usd
carm Proceeds From Failed Sale Leaseback Transaction
ProceedsFromFailedSaleLeasebackTransaction
686000 usd
carm Proceeds From Failed Sale Leaseback Transaction
ProceedsFromFailedSaleLeasebackTransaction
1020000 usd
carm Payment Of Finance Liability Failed Sale Leaseback Transaction
PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction
645000 usd
carm Payment Of Finance Liability Failed Sale Leaseback Transaction
PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction
88000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
52000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2286000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1425000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
64112000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-37243000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
52189000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77605000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24194000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40362000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76383000 usd
us-gaap Interest Paid Net
InterestPaidNet
105000 usd
us-gaap Interest Paid Net
InterestPaidNet
88000 usd
carm Noncash Or Part Noncash Acquisition Equity Assumed
NoncashOrPartNoncashAcquisitionEquityAssumed
0 usd
carm Noncash Or Part Noncash Acquisition Equity Assumed
NoncashOrPartNoncashAcquisitionEquityAssumed
122204000 usd
us-gaap Notes Reduction
NotesReduction
0 usd
us-gaap Notes Reduction
NotesReduction
42447000 usd
carm Noncash Or Part Noncash Reverse Recapitalization Costs In Accrued Expenses
NoncashOrPartNoncashReverseRecapitalizationCostsInAccruedExpenses
0 usd
carm Noncash Or Part Noncash Reverse Recapitalization Costs In Accrued Expenses
NoncashOrPartNoncashReverseRecapitalizationCostsInAccruedExpenses
611000 usd
carm Noncash Or Part Noncash Unrealized Gain Loss On Marketable Securities
NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities
0 usd
carm Noncash Or Part Noncash Unrealized Gain Loss On Marketable Securities
NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities
306000 usd
carm Non Cash Deferred Financing Costs Accounts Payable
NonCashDeferredFinancingCostsAccountsPayable
0 usd
carm Non Cash Deferred Financing Costs Accounts Payable
NonCashDeferredFinancingCostsAccountsPayable
86000 usd
carm Non Cash Deferred Financing Costs Accrued Expenses
NonCashDeferredFinancingCostsAccruedExpenses
0 usd
carm Non Cash Deferred Financing Costs Accrued Expenses
NonCashDeferredFinancingCostsAccruedExpenses
60000 usd
carm Noncash Or Part Noncash Transaction Reclassification Of Debt Finance Costs
NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts
4000 usd
carm Noncash Or Part Noncash Transaction Reclassification Of Debt Finance Costs
NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4337000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
908000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
1660000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-275200000 usd
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
40400000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant areas that require management’s estimates include accrued research and development expenses.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of credit risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</span></div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2024Q2 carm Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
1279000 usd
CY2023Q4 carm Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
278000 usd
CY2024Q2 carm Vendor Credit Current
VendorCreditCurrent
4000000 usd
CY2023Q4 carm Vendor Credit Current
VendorCreditCurrent
0 usd
CY2024Q2 carm Receivable Due From Collaborative Arrangement Current
ReceivableDueFromCollaborativeArrangementCurrent
2000000 usd
CY2023Q4 carm Receivable Due From Collaborative Arrangement Current
ReceivableDueFromCollaborativeArrangementCurrent
0 usd
CY2024Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1548000 usd
CY2023Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
891000 usd
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
725000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
402000 usd
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
807000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1295000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10359000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2866000 usd
CY2024Q2 carm Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2803000 usd
CY2023Q4 carm Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3131000 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
414000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1366000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1562000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3100000 usd
CY2024Q2 carm Accrued Termination Fee Current
AccruedTerminationFeeCurrent
4409000 usd
CY2023Q4 carm Accrued Termination Fee Current
AccruedTerminationFeeCurrent
0 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
53000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
65000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9241000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7662000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
3154000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
2875000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1008000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
593000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
159000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
88000 usd
carm Finance Lease Cost
FinanceLeaseCost
1167000 usd
carm Finance Lease Cost
FinanceLeaseCost
681000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
672000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
653000 usd
us-gaap Lease Cost
LeaseCost
4993000 usd
us-gaap Lease Cost
LeaseCost
4209000 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M12D
CY2024Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M24D
CY2023Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M12D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.098
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.096
CY2024Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.090
CY2023Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.090
us-gaap Operating Lease Payments
OperatingLeasePayments
3203000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
2584000 usd
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
159000 usd
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
88000 usd
carm Financing Cash Used In Finance Leases
FinancingCashUsedInFinanceLeases
906000 usd
carm Financing Cash Used In Finance Leases
FinancingCashUsedInFinanceLeases
213000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1177000 usd
CY2024Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
631000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
219000 usd
CY2024Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
1261000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
226000 usd
CY2024Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
20000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
233000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
240000 usd
CY2024Q2 carm Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
184000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2279000 usd
CY2024Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1912000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
305000 usd
CY2024Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
127000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1974000 usd
CY2024Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
1785000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6023370 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.94
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3810 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3674365 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1008687 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.70
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8685238 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.93
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M20D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2018000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3487670 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.19
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M24D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1517000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.45
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.43
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
625000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
330000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1682000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
595000 usd
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
11800000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9200000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3600000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12600000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6800000 usd
CY2024Q2 carm Revenue Remaining Performance Obligation Research And Development Amount
RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount
42339000 usd
CY2024Q2 carm Revenue Remaining Performance Obligation Option Rights Amount
RevenueRemainingPerformanceObligationOptionRightsAmount
41250000 usd
CY2024Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
83589000 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
46413000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
47459000 usd
carm Contract With Customer Liability Deferral Of Revenue
ContractWithCustomerLiabilityDeferralOfRevenue
6090000 usd
carm Contract With Customer Liability Deferral Of Revenue
ContractWithCustomerLiabilityDeferralOfRevenue
5760000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-10594000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-6803000 usd
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
41909000 usd
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
46416000 usd
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001485003-24-000015-index-headers.html Edgar Link pending
0001485003-24-000015-index.html Edgar Link pending
0001485003-24-000015.txt Edgar Link pending
0001485003-24-000015-xbrl.zip Edgar Link pending
carm-20240630.htm Edgar Link pending
carm-20240630.xsd Edgar Link pending
carm-20240630xexx311.htm Edgar Link pending
carm-20240630xexx312.htm Edgar Link pending
carm-20240630xexx321.htm Edgar Link pending
carm-20240630xexx322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
carm-20240630_cal.xml Edgar Link unprocessable
carm-20240630_def.xml Edgar Link unprocessable
carm-20240630_lab.xml Edgar Link unprocessable
carm-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
carm-20240630_htm.xml Edgar Link completed
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending